Company Overview - ProQR is a clinical-stage biotech company focused on developing RNA-based therapies for genetic diseases, utilizing its proprietary Axiomer RNA editing platform to make precise changes at the RNA level [3][12] - The company's lead program, AX-0810, targets NTCP, a liver transport protein, aiming to lower bile acid levels to address cholestatic liver diseases such as primary sclerosing cholangitis and biliary atresia [1][12] Pipeline and Development - ProQR is advancing AX-0810 through a Phase 1 dosing trial, with target engagement data expected in the first half of 2026 [7] - Initial updates on AX-0810 have shown no safety signals after four weeks of dosing, aligning with preclinical expectations [8] - Beyond AX-0810, ProQR is developing AX-2402 for Rett syndrome and AX-2911 for metabolic dysfunction-associated steatohepatitis, with plans to advance AX-2402 into human studies by the first half of 2027 [9] Strategic Collaborations - ProQR has a strategic collaboration with Eli Lilly, focusing on RNA editing therapies for genetically defined targets, which generated $4.5 million in milestone payments in 2025 [10] Market Potential and Analyst Outlook - Analysts, including Oppenheimer's Kostas Biliouris, view ProQR's current share price of $1.37 as an attractive entry point, with a potential upside of 50-100% based on upcoming data [11][12] - The consensus rating for ProQR is a 'Strong Buy', with an average price target of $8.20, indicating a potential surge of approximately 500% over the next year [13] Financial Performance - ProQR's valuation currently assigns minimal credit to AX-0810, which could represent a multi-billion dollar commercial opportunity if successful [12]

Core Insights - ProQR Therapeutics reported significant clinical advancements in 2025, particularly with AX-0810 for cholestatic diseases entering Phase 1 trials, and aims to provide target engagement data in the first half of 2026 [2][3] - The company has strengthened its pipeline with new development candidates AX-2402 for Rett syndrome and AX-2911 for MASH, alongside a successful collaboration with Eli Lilly, achieving $4.5 million in milestones [2][8] Financial Highlights - As of December 31, 2025, ProQR held cash and cash equivalents of approximately €92.4 million, down from €149.4 million in 2024 [11] - The net cash used in operating activities for 2025 was €52.8 million, compared to €36.4 million in 2024 [11] - The net loss for 2025 was €42.2 million, or €0.40 per diluted share, an increase from €27.8 million, or €0.32 per diluted share, in 2024 [12] Clinical Development - AX-0810 is currently in a Phase 1 multiple-dose escalation study in healthy volunteers, with initial safety and pharmacokinetic data reported [6] - The company plans to include a PSC patient cohort in the ongoing Phase 1 trial after completing the healthy volunteer cohorts [6] - AX-2402 has shown promising preclinical results in a Rett syndrome mouse model, with plans to initiate first-in-human clinical testing in the first half of 2027 [6][12] Pipeline Expansion - AX-2402 targets the R270X mutation in MECP2 to restore normal protein function for Rett syndrome [4] - AX-2911 aims to address the I148M mutation in PNPLA3, a significant genetic risk factor for fatty liver disease, demonstrating over 80% reduction in hepatic fat content in preclinical studies [5][7] Strategic Collaborations - The collaboration with Eli Lilly is expected to continue in 2026, with potential data updates and additional milestone payments anticipated [8]

Core Insights - ProQR Therapeutics N.V. is focused on developing transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform [1][4] - The company will present at the Citizens Life Sciences Conference on March 11, 2026, at 3:25pm ET [1] - Axiomer technology enables specific single nucleotide changes in RNA, potentially leading to new medicines for various diseases [3][4] Company Overview - ProQR is dedicated to creating RNA therapies that can reverse mutations or modulate protein expression, addressing both rare and prevalent diseases with unmet medical needs [4] - The Axiomer platform utilizes the ADAR (Adenosine Deaminase Acting on RNA) machinery found in human cells to facilitate precise RNA edits [3][4] - The company aims to grow its pipeline with a focus on patient needs and innovative solutions [4]

Core Viewpoint - ProQR Therapeutics is undergoing changes in its Board composition as part of its commitment to corporate governance and long-term succession planning, with two co-founders rotating off the Board at the upcoming Annual General Meeting [1][2]. Group 1: Board Changes - Dinko Valerio and Alison Lawton will step down from the Board at the next AGM as their terms conclude [1]. - An executive search firm has been engaged to identify new candidates for the Board to support long-term value creation [2]. - The Board regularly reviews its composition to ensure a balance of skills and experience, having appointed two new members in the last three years [3]. Group 2: Axiomer Technology - ProQR is pioneering a next-generation RNA base editing technology called Axiomer, which aims to create a new class of medicines for various diseases [4][5]. - Axiomer Editing Oligonucleotides (EONs) facilitate specific single nucleotide changes in RNA, potentially correcting disease-causing mutations and modulating protein expression [4]. Group 3: Company Mission - ProQR is dedicated to transforming lives through innovative RNA therapies, focusing on unmet medical needs for both rare and prevalent diseases [5].

Core Insights - ProQR Therapeutics announced initial safety and pharmacokinetic (PK) data from its Phase 1 trial of AX-0810, indicating a positive early milestone for the company [2][5] - The company is advancing its pipeline with new development candidates for AX-2402 and AX-2911, targeting Rett syndrome and metabolic-associated steatohepatitis (MASH) respectively [7][12] AX-0810 Phase 1 Study - AX-0810 is a lead investigational RNA editing oligonucleotide targeting NTCP for cholestatic diseases [3][16] - The Phase 1 study is a randomized, double-blind, placebo-controlled trial with up to 33 participants, assessing safety, tolerability, and pharmacokinetics [4] - Initial data from the first cohort (3 mg/kg) showed no serious adverse events and PK observations aligned with non-clinical data, supporting continued dosing [5][9] Pipeline Progress - ProQR has selected development candidates for AX-2402 targeting MECP2 for Rett syndrome and AX-2911 targeting PNPLA3 for MASH [10][12] - AX-2402 demonstrated significant functional improvements in a mouse model, supported by funding from the Rett Syndrome Research Trust [11] - AX-2911 showed over 80% reduction in hepatic fat content in a humanized mouse model, outperforming a clinical-stage therapy [13] Strategic Collaboration - The collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, validating ProQR's Axiomer platform and providing non-dilutive capital [14] Corporate Outlook - ProQR plans to report target engagement data for AX-0810 in the first half of 2026 and initiate a patient cohort in the trial [6][18] - The company aims to advance AX-2402 to a first-in-human trial in the first half of 2027 and continue to strengthen its financial position [18]

Company Overview - ProQR is pioneering ADAR-mediated RNA editing with its Axiomer platform, moving from invention to clinical trials [11, 17] - The company has a strong intellectual property estate and strategic partnerships with Eli Lilly and Rett Syndrome Research Trust [17, 135] - ProQR's cash and cash equivalents were €119.8 million as of the end of Q2 2025, providing a runway into mid-2027 [18, 136] Pipeline and Clinical Development - AX-0810, targeting NTCP for cholestatic diseases, has received CTA authorization and is entering a Phase 1 clinical trial [17, 21] - The Phase 1 trial aims to establish safety, PK, and target engagement in healthy volunteers [21] - AX-2402, for Rett syndrome, is rapidly advancing, positioning ProQR at the forefront of neurological RNA editing medicines [21] AX-0810 and Cholestatic Diseases - Cholestatic diseases, including Primary Sclerosing Cholangitis (PSC) affecting approximately 80,000 adults and Congenital Biliary Atresia affecting approximately 20,000 pediatrics, have high unmet medical needs [24, 38] - AX-0810 is a first-in-class RNA editing therapy designed to modulate the NTCP channel, limiting bile acid uptake while preserving other channel functions [31] - The therapeutic goal of AX-0810 is to reduce inflammation and fibrosis, alleviate symptoms in PSC and BA, and prevent or delay cirrhosis, organ failure, and transplant [36] AX-0810 Clinical Trial Design - The Phase 1 trial is a multiple ascending dose (MAD) study with N=33 participants (24 on treatment, 9 on placebo) across three cohorts: 3mg/kg, 6mg/kg, and 9mg/kg (TBC) [103, 104] - The trial will assess safety, tolerability, and PK of AX-0810, and confirm target engagement as measured by changes in bile acid levels, bile acid profile, and TUDCA challenge [107] - Initial Cohort 1 safety, tolerability, and PK data are expected toward the end of 2025, with target engagement data on all cohorts anticipated in H1 2026 [107, 131]

Core Insights - ProQR Therapeutics has received authorization from the Central Committee on Research Involving Human Subjects (CCMO) for a Phase 1 Clinical Trial Application (CTA) for AX-0810, targeting cholestatic diseases [1][2] - AX-0810 is the first investigational RNA editing oligonucleotide (EON) from ProQR's Axiomer™ platform, aimed at reducing toxic bile acid accumulation in the liver [6][10] Company Overview - ProQR Therapeutics is focused on developing transformative RNA therapies using its proprietary Axiomer technology, which utilizes the body's own ADAR enzymes for RNA editing [1][10] - The company aims to create a new class of medicines for both rare and prevalent diseases with unmet medical needs [10] Clinical Development - The Phase 1 study of AX-0810 will assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) through biomarkers to establish proof of target engagement [2][6] - The trial will be conducted in the Netherlands, and dosing is set to begin following the CTA approval [2] Upcoming Events - ProQR will host a virtual Investor and Analyst Event on November 3, 2025, to discuss the clinical development of AX-0810 [2][8] - The event will feature presentations from ProQR management and Professor Henkjan J. Verkade, a key opinion leader in pediatric gastroenterology [2][4]

Core Insights - ProQR Therapeutics is focused on developing transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform [1][3] - The company will participate in several upcoming investor conferences, providing opportunities for engagement with investors [1][5] Company Overview - ProQR Therapeutics is dedicated to creating RNA therapies that can address both rare and prevalent diseases with unmet medical needs [3] - The Axiomer technology utilizes the human cell's own ADAR machinery to make precise single nucleotide edits in RNA, potentially reversing mutations or modulating protein expression [2][3] Upcoming Events - ProQR will present at the H.C. Wainwright Genetic Medicines Virtual Conference on October 14-15, 2025, with presentations available on demand starting October 14 [5] - The company will also participate in the H.C. Wainwright Liver Disease Virtual Conference on October 21-22, 2025, and the Chardan's 9th Annual Genetic Medicines Conference on October 21, 2025 [5]